Hints and tips:
Related Special Reports
Related Topics
...Chief executives at AbbVie, Eli Lilly, and Johnson & Johnson all earned more than Soriot in 2023....
...“The legal case against AbbVie concerns the fundamental question to what extent pharmaceutical companies like AbbVie are free to set and maintain the prices of the drugs they offer,” the PAF said....
...AbbVie’s shares were down nearly 15 per cent in pre-market trading on Thursday. ImmunoGen’s stock price is up 227 per cent year to date....
...US pharmaceuticals group AbbVie announced its second takeover in less than a week, scooping up neurological drug developer Cerevel Therapeutics in a transaction worth more than $8bn....
...AbbVie announced on November 30 it would acquire ovarian cancer drugmaker ImmunoGen in a deal worth about $10bn....
...Emblaveo was developed in partnership with US pharma company AbbVie and with financial support from US and EU public bodies....
...Pharma: Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie will also report earnings before the market opens....
...The company has set out to develop the largest injectibles business in the market, taking on competitors such as AbbVie and Merz....
...In the pharmaceutical industry, big companies including AstraZeneca, AbbVie and Bristol Myers Squibb have announced about $25bn worth of biotech-related deals....
...Last year a US appeals court ruled that AbbVie’s use of a patent thicket did not unlawfully block competition....
...Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie are also expected to release earnings....
...AbbVie’s Humira, used for a range of autoimmune diseases, became the world’s best-selling drug but has recently had its market exclusivity expire....
...Royal Caribbean Group Q4, Sanofi Q4, Shell Q4, Sumitomo Mitsui Financial Group Q3, United States Steel Q4 Friday France: monthly industrial production figures US: February employment update Results: AbbVie...
...US drugmakers AbbVie and Eli Lilly have become the first pharmaceutical groups to pull out of a pricing agreement with the UK government in protest at a sharp rise in clawback payments....
...Evan Seigerman, analyst at BMO Capital Markets, said drugs developed by Bristol, Pfizer, Lilly, Merck, AbbVie, and Amgen were likely to be on the initial CMS list....
...These include a potential oral drug similar to AbbVie’s megablockbuster Humira injection, used to treat arthritis and Crohn’s disease, which Hudson said could end up being the biggest medicine ever created...
...But the one that made $200bn for AbbVie cannot be right. john.gapper@ft.com...
...News round-up BAT to take £25bn hit on US cigarette brands (FT) AbbVie to buy drugmaker Cerevel for $8bn (Reuters) ExxonMobil aims for higher oil production with capital spending boost (FT) Investors...
...News round-up Drugmaker AbbVie to buy ImmunoGen in $10.1bn deal (FT) PwC fined $7mn over exam cheating by China and Hong Kong staff (FT) UK to probe Abu Dhabi-backed bid for Telegraph group (FT) Ex-Goldman...
...Yet despite a 2014 partnership with US pharma company AbbVie, extended in 2021, Calico has yet to bring any drugs to the market....
...Pascal Soriot, AstraZeneca’s chief executive, said in February that drugmakers should not be made to pay for the “explosion” of NHS costs, while US pharma groups Eli Lilly and AbbVie quit the pricing agreement...
...In March Pfizer swooped on Seagen, announcing a deal for a total enterprise value of $43bn, which was the largest pharmaceutical transaction announced since AbbVie agreed to buy Allergan in 2019....
...AbbVie and Eli Lilly have withdrawn from the scheme (a symbolic protest given the punitively high statutory backstop rebate)....
...Humira, the world’s best-selling drug, which has amassed $200bn in global sales for AbbVie, faced competition in Europe in 2018....
...AbbVie and Eli Lilly’s stand is a largely symbolic gambit ahead of renegotiation of the voluntary UK scheme which expires this year....
International Edition